Aerpio Pharmaceuticals (OTCMKTS:ARPO) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Aerpio Pharmaceuticals (OTCMKTS:ARPO) from a buy rating to a hold rating in a research note published on Tuesday, Zacks.com reports.

According to Zacks, “Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company’ product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. “

Separately, HC Wainwright reaffirmed a hold rating and set a $1.00 price objective on shares of Aerpio Pharmaceuticals in a report on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $5.00.

OTCMKTS ARPO opened at $0.63 on Tuesday. The company has a fifty day simple moving average of $0.80 and a 200 day simple moving average of $1.51. Aerpio Pharmaceuticals has a 1 year low of $0.61 and a 1 year high of $4.25.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.04.

Several institutional investors have recently made changes to their positions in ARPO. Vanguard Group Inc. increased its position in shares of Aerpio Pharmaceuticals by 9.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,300,889 shares of the company’s stock worth $1,183,000 after purchasing an additional 108,749 shares in the last quarter. Alambic Investment Management L.P. acquired a new stake in Aerpio Pharmaceuticals in the 1st quarter valued at about $85,000. BlackRock Inc. increased its position in Aerpio Pharmaceuticals by 78.8% in the 2nd quarter. BlackRock Inc. now owns 165,222 shares of the company’s stock valued at $150,000 after acquiring an additional 72,796 shares in the last quarter. Jane Street Group LLC increased its position in Aerpio Pharmaceuticals by 216.3% in the 4th quarter. Jane Street Group LLC now owns 81,984 shares of the company’s stock valued at $139,000 after acquiring an additional 56,065 shares in the last quarter. Finally, Panagora Asset Management Inc. increased its position in Aerpio Pharmaceuticals by 390.2% in the 2nd quarter. Panagora Asset Management Inc. now owns 64,074 shares of the company’s stock valued at $58,000 after acquiring an additional 51,003 shares in the last quarter. Institutional investors and hedge funds own 0.37% of the company’s stock.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Recommended Story: Ex-Dividend

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.